Paion AG Stock price Xetra

Equities

PA8

DE000A3E5EG5

Biotechnology & Medical Research

End-of-day quote Xetra 07:00:00 2023-10-31 pm EDT 5-day change 1st Jan Change
0.36 EUR +4.35% Intraday chart for Paion AG -.--% -.--%
Sales 2023 * 13.99M 15.09M Sales 2024 * 27.56M 29.74M Capitalization 253K 273K
Net income 2023 * -15M -16.19M Net income 2024 * -1M -1.08M EV / Sales 2023 * 1.98 x
Net Debt 2023 * 27.4M 29.57M Net Debt 2024 * 38.3M 41.33M EV / Sales 2024 * 1.4 x
P/E ratio 2023 *
-0.02 x
P/E ratio 2024 *
-0.15 x
Employees 64
Yield 2023 *
-
Yield 2024 *
-
Free-Float 90.91%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.35%
6 months-91.31%
More quotes
1 year
0.22
Extreme 0.224
8.80
3 years
0.22
Extreme 0.224
21.70
5 years
0.22
Extreme 0.224
34.10
10 years
0.22
Extreme 0.224
40.50
More quotes
Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.0355 EUR
Average target price
9.85 EUR
Spread / Average Target
+27,646.48%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Paion AG
  4. Stock Paion AG - Xetra